Sun Pharma announced the acquisition of Organon & Company for an enterprise value of $11.75 billion (approx. ₹1,11,625 Crore). The deal expands Sun's footprint in women's health and biosimilars across 140 countries, including a significant entry into China. The transaction is expected to close in six to nine months and be EPS accretive from the first year.
Sun Pharmaceutical's US subsidiary will acquire 100% of Organon & Co. for ₹37,649 Crore ($3.99B equity value) in an all-cash merger. The deal, valued at $11.75B enterprise value, strengthens Sun's global portfolio in women's health and biosimilars. Completion is expected in early 2027, subject to regulatory and shareholder approvals.
Sun Pharma has agreed to acquire 100% of Organon & Co. for US$ 14.00 per share in an all-cash deal valued at ₹110,450 Crore (EV). The acquisition marks Sun Pharma's entry into biosimilars and significantly expands its global Women's Health portfolio. The transaction is expected to close in early 2027.
